Fingolimod-Associated Intracerebral Lymphoproliferative DisorderBaharnoori, Moogeh, MD, PhD1; Mahajan, Rahul, MD2; Solomon, Issac H., MD, PhD3; Pinkus, Geraldine, MD3; Houtchens, Maria, MD1,2,*American Journal of Therapeutics: October 27, 2017 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/MJT.0000000000000694 Therapeutic Challenge: PDF Only Abstract Author InformationAuthors Article MetricsMetrics Most epidemiological studies indicate that incidence of cancer in multiple sclerosis patients is lower than general population. However these studies were performed prior to the emergence of disease-modifying therapies (DMTs). The incidence of cancer may be influenced by newer generation DMTs which are immunomodulatory or immunosuppressant. We describe an atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod. As worldwide usage of oral and infusion DMTs increases, heightened clinical suspicion and early recognition of these serious adverse events remain crucial. 1Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Departments of 2Neurology and 3Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Address for correspondence: Partners Multiple Sclerosis Center, 60 Fenwood Road, Building for Transformative Medicine, Boston, MA 02115-6128. E-mail: mhoutchens@BWH.harvard.edu The authors have no conflicts of interest to declare. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.